Quizartinib Dihydrochloride Patent Expiration
Quizartinib Dihydrochloride is Used for treatment of newly diagnosed FLT3-ITD positive acute myeloid leukemia in adult patients. It was first introduced by Daiichi Sankyo Inc
Quizartinib Dihydrochloride Patents
Given below is the list of patents protecting Quizartinib Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vanflyta | US7820657 | Imidazolothiazole compounds for the treatment of disease | Sep 26, 2028 | Daiichi Sankyo Inc |
| Vanflyta | US7968543 | Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease | Aug 15, 2029 | Daiichi Sankyo Inc |
| Vanflyta | US8129374 | Method of using imidazolothiazole compounds for the treatment of disease | Mar 16, 2027 | Daiichi Sankyo Inc |
| Vanflyta | US8357690 | Methods of treatment using combination therapy | Feb 26, 2031 | Daiichi Sankyo Inc |
| Vanflyta | US8557810 | Imidazolothiazole compounds for the treatment of disease | Mar 16, 2027 | Daiichi Sankyo Inc |
| Vanflyta | US8836218 | Methods of treatment using combination therapy | Mar 23, 2030 | Daiichi Sankyo Inc |
| Vanflyta | US8865710 | Methods of treating proliferative diseases | Aug 15, 2029 | Daiichi Sankyo Inc |
| Vanflyta | US8883783 | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith | Mar 16, 2027 | Daiichi Sankyo Inc |
| Vanflyta | US9555040 | Methods of treating proliferative diseases | May 14, 2030 | Daiichi Sankyo Inc |
| Vanflyta | US9585892 | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith | Mar 16, 2027 | Daiichi Sankyo Inc |
| Vanflyta | US9675549 | Tablet containing composite with cyclodextrin | Sep 30, 2033 | Daiichi Sankyo Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Quizartinib Dihydrochloride's patents.
Latest Legal Activities on Quizartinib Dihydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Quizartinib Dihydrochloride.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jul, 2024 | US9555040 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Jul, 2024 | US8357690 |
| Second letter to regulating agency to determine regulatory review period | 02 Feb, 2024 | US8557810 |
| Second letter to regulating agency to determine regulatory review period | 02 Feb, 2024 | US8836218 |
| Second letter to regulating agency to determine regulatory review period | 02 Feb, 2024 | US8357690 |
| Second letter to regulating agency to determine regulatory review period | 02 Feb, 2024 | US7820657 |
| Second letter to regulating agency to determine regulatory review period | 02 Feb, 2024 | US8129374 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US7820657 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US8129374 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US8357690 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳